Cost-effectiveness of carbapenem-resistant Enterobacteriaceae (CRE) surveillance in Maryland.
Journal
Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
23
10
2021
medline:
20
9
2022
entrez:
22
10
2021
Statut:
ppublish
Résumé
We analyzed the efficacy, cost, and cost-effectiveness of predictive decision-support systems based on surveillance interventions to reduce the spread of carbapenem-resistant Enterobacteriaceae (CRE). We developed a computational model that included patient movement between acute-care hospitals (ACHs), long-term care facilities (LTCFs), and communities to simulate the transmission and epidemiology of CRE. A comparative cost-effectiveness analysis was conducted on several surveillance strategies to detect asymptomatic CRE colonization, which included screening in ICUs at select or all hospitals, a statewide registry, or a combination of hospital screening and a statewide registry. We investigated 51 ACHs, 222 LTCFs, and skilled nursing facilities, and 464 ZIP codes in the state of Maryland. The model was informed using 2013-2016 patient-mix data from the Maryland Health Services Cost Review Commission. This model included all patients that were admitted to an ACH. On average, the implementation of a statewide CRE registry reduced annual CRE infections by 6.3% (18.8 cases). Policies of screening in select or all ICUs without a statewide registry had no significant impact on the incidence of CRE infections. Predictive algorithms, which identified any high-risk patient, reduced colonization incidence by an average of 1.2% (3.7 cases) without a registry and 7.0% (20.9 cases) with a registry. Implementation of the registry was estimated to save $572,000 statewide in averted infections per year. Although hospital-level surveillance provided minimal reductions in CRE infections, regional coordination with a statewide registry of CRE patients reduced infections and was cost-effective.
Identifiants
pubmed: 34674791
pii: S0899823X21003615
doi: 10.1017/ice.2021.361
pmc: PMC9023597
mid: NIHMS1752629
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1162-1170Subventions
Organisme : NCEZID CDC HHS
ID : U01 CK000536
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000589
Pays : United States
Références
Am J Epidemiol. 2016 Mar 1;183(5):471-9
pubmed: 26861238
Virulence. 2017 May 19;8(4):417-426
pubmed: 27813699
Open Forum Infect Dis. 2020 Feb 15;7(3):ofaa056
pubmed: 32166095
Am J Epidemiol. 1997 Jun 15;145(12):1127-37
pubmed: 9199543
Infect Control Hosp Epidemiol. 2014 Apr;35(4):440-2
pubmed: 24602954
N Engl J Med. 2001 May 10;344(19):1427-33
pubmed: 11346807
Am J Infect Control. 2014 Jun;42(6):612-20
pubmed: 24837111
Am J Infect Control. 2017 Nov 1;45(11):1177-1182
pubmed: 28757088
Infect Control Hosp Epidemiol. 2006 Mar;27(3):228-32
pubmed: 16532408
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Infect Control Hosp Epidemiol. 2015 Oct;36(10):1163-72
pubmed: 26138329
J Clin Microbiol. 2005 Apr;43(4):2034; author reply 2034-5
pubmed: 15815056
Eur J Clin Microbiol Infect Dis. 1999 Jul;18(7):461-6
pubmed: 10482021
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11157-62
pubmed: 16055564
Cleve Clin J Med. 2013 Apr;80(4):225-33
pubmed: 23547093
Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):782-6
pubmed: 12461587
Clin Infect Dis. 2019 Feb 15;68(5):873-884
pubmed: 30475989
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Antimicrob Agents Chemother. 2008 Mar;52(3):1028-33
pubmed: 18086836
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1491-1493
pubmed: 30269700
Clin Infect Dis. 2021 Feb 1;72(3):431-437
pubmed: 31970393
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
Clin Infect Dis. 2020 Feb 14;70(5):843-849
pubmed: 31070719
Emerg Infect Dis. 2015 Oct;21(10):1725-32
pubmed: 26402744
Lancet. 2010 Dec 4;376(9756):1910-5
pubmed: 21122910
Science. 2000 Jan 28;287(5453):650-4
pubmed: 10649998
J Antimicrob Chemother. 2007 Nov;60(5):1124-30
pubmed: 17884829
Am J Gastroenterol. 2015 Dec;110(12):1666-74
pubmed: 26526083
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Infect Control Hosp Epidemiol. 2012 Aug;33(8):817-30
pubmed: 22759550
Clin Infect Dis. 2011 Apr 1;52(7):848-55
pubmed: 21317398
Clin Infect Dis. 2015 Apr 15;60(8):1153-61
pubmed: 25537877
Clin Microbiol Infect. 2017 Jan;23(1):48.e9-48.e16
pubmed: 27642178
Arch Intern Med. 2002 Jan 28;162(2):185-90
pubmed: 11802752